Opportunities for Elan’s Alzheimer’s drug

ELAN reiterated yesterday that a substantial opportunity exists, on a commercial basis, for its planned series of treatments for Alzheimer’s disease — all of which are currently at various testing stages.

Analysts have suggested that Elan’s most progressed Alzheimer’s treatment — AAB-001 (bapineuzumab) — could generate up to $6.5 billion (€4.13bn) in group revenues within five years of being commercialised.

However, a spokesperson for Elan said yesterday it is too early to be talking about such numbers.